keyword
MENU ▼
Read by QxMD icon Read
search

renal cancer model

keyword
https://www.readbyqxmd.com/read/28428688/modulation-of-angiogenesis-proliferative-response-and-apoptosis-by-%C3%AE-sitosterol-in-rat-model-of-renal-carcinogenesis
#1
Ramalingam Sharmila, Ganapathy Sindhu
As expanded understanding of molecular tumor characteristics, which drive renal cancer growth and progression gives a promising future for renal carcinoma therapy. The objective of the present study was designed to examine the effect of β-sitosterol on a rat model of experimental renal carcinogenesis. Renal carcinogenesis was induced in rats treated with N-diethylnitrosamine (DEN; 200 mg/kg bw single i.p., injection) and ferric nitrilotriacetate (Fe-NTA; 9 mg Fe/kg bw i.p., twice a week for 16 weeks). β-sitosterol pretreatment (20 mg/kg bw in 0...
June 2017: Indian Journal of Clinical Biochemistry: IJCB
https://www.readbyqxmd.com/read/28427859/the-role-of-c-met-in-prognosis-and-clinicopathology-of-renal-cell-carcinoma-results-from-a-single-centre-study-and-systematic-review
#2
Shouzhen Chen, Yaofeng Zhu, Jianfeng Cui, Yong Wang, Yangyang Xia, Jing Song, Shanshan Cheng, Changkuo Zhou, Dongqing Zhang, Bing Zhang, Benkang Shi
BACKGROUND AND OBJECTIVES: The c-Met proto-oncogene pathway plays an important role in the progression of various cancers. However, the effect of the c-Met pathway on renal cell carcinoma (RCC) remains controversial. We decided to clarify the role of c-Met in prognosis and clinicopathology of RCC. METHODS: A total of 10 pairs of tumour and adjacent tissues were obtained from patients with primary RCC between 2013 and 2014 and tissue microarrays to assess c-Met expression in tumour tissues from 90 patients with RCC by Western blot and immunohistochemical staining...
April 18, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28424213/magnesium-improves-cisplatin-mediated-tumor-killing-while-protecting-against-cisplatin-induced-nephrotoxicity
#3
Gopal Kumar, Malvika H Solanki, Xiangying Xue, Rachel Mintz, Swati Madankumar, Proydot K Chatterjee, Christine N Metz
Approximately 30% of all cancer patients treated with cisplatin, a widely used, broad-spectrum chemotherapeutic agent, experience acute kidney injury (AKI). Almost all patients receiving cisplatin have magnesium (Mg) losses, which are proposed to aggravate AKI. Currently, there are no methods to successfully treat or prevent cisplatin-AKI. While Mg supplementation has been shown to reduce AKI in experimental models and several small clinical trials, the effects of Mg status on tumor outcomes in immunocompetent tumor-bearing mice and humans have not been investigated...
April 19, 2017: American Journal of Physiology. Renal Physiology
https://www.readbyqxmd.com/read/28423637/apigenin-inhibits-renal-cell-carcinoma-cell-proliferation
#4
Shuai Meng, Yi Zhu, Jiang-Feng Li, Xiao Wang, Zhen Liang, Shi-Qi Li, Xin Xu, Hong Chen, Ben Liu, Xiang-Yi Zheng, Li-Ping Xie
Apigenin, a natural flavonoid found in vegetables and fruits, has antitumor activity in several cancer types. The present study evaluated the effects and mechanism of action of apigenin in renal cell carcinoma (RCC) cells. We found that apigenin suppressed ACHN, 786-0, and Caki-1 RCC cell proliferation in a dose- and time-dependent manner. A comet assay suggested that apigenin caused DNA damage in ACHN cells, especially at higher doses, and induced G2/M phase cell cycle arrest through ATM signal modulation...
March 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/28423523/mir-106b-5p-promotes-renal-cell-carcinoma-aggressiveness-and-stem-cell-like-phenotype-by-activating-wnt-%C3%AE-catenin-signalling
#5
Jun Lu, Jin-Huan Wei, Zi-Hao Feng, Zhen-Hua Chen, Yong-Qian Wang, Yong Huang, Yong Fang, Yan-Ping Liang, Jun-Jie Cen, Yi-Hui Pan, Bing Liao, Wen-Fang Chen, Wei Chen, Jun-Hang Luo
PURPOSE: To examine the role of miR-106b-5p in regulating the cancer stem-cell-like phenotype in clear cell renal cell carcinomas (ccRCC). EXPERIMENTAL DESIGN: Real-time PCR was performed to evaluate miR-106b-5p levels in ccRCC cell lines and patients specimens. A series of in vivo and in vitro assays were performed to confirm the effect of miR-106b-5p on ccRCC stemness phenotype. RESULTS: ccRCC cells and tissues expressed more miR-106b-5p than normal controls...
March 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28418451/cost-effectiveness-of-common-diagnostic-approaches-for-evaluation-of-asymptomatic-microscopic-hematuria
#6
Joshua A Halpern, Bilal Chughtai, Hassan Ghomrawi
Importance: Asymptomatic microscopic hematuria (AMH) is highly prevalent and may signal occult genitourinary (GU) malignant abnormality. Common diagnostic approaches differ in their costs and effectiveness in detecting cancer. Given the low prevalence of GU malignant abnormality among patients with AMH, it is important to quantify the cost implications of detecting cancer for each approach. Objective: To estimate the effectiveness, costs, and incremental cost per cancer detected (ICCD) for 4 common diagnostic approaches evaluating AMH...
April 17, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28416753/synergistic-effects-of-the-immune-checkpoint-inhibitor-ctla-4-combined-with-the-growth-inhibitor-lycorine-in-a-mouse-model-of-renal-cell-carcinoma
#7
Xiezhao Li, Peng Xu, Chongshan Wang, Naijin Xu, Abai Xu, Yawen Xu, Takuya Sadahira, Motoo Araki, Koichiro Wada, Eiji Matsuura, Masami Watanabe, Junxia Zheng, Pinghua Sun, Peng Huang, Yasutomo Nasu, Chunxiao Liu
Renal cell carcinoma (RCC) management has undergone a major transformation over the past decade; immune checkpoint inhibitors are currently undergoing clinical trials and show promising results. However, the effectiveness of immune checkpoint inhibitors in patients with metastatic RCC (mRCC) is still limited. Lycorine, an alkaloid extracted from plants of the Amaryllidaceae family, is touted as a potential anti-cancer drug because of its demonstrative growth inhibition capacity (induction of cell cycle arrest and inhibition of vasculogenic mimicry formation)...
March 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28416734/the-angiotensin-receptor-blocker-losartan-inhibits-mammary-tumor-development-and-progression-to-invasive-carcinoma
#8
Rhiannon Coulson, Seng H Liew, Angela A Connelly, Nicholas S Yee, Siddhartha Deb, Beena Kumar, Ana C Vargas, Sandra A O'Toole, Adam C Parslow, Ashleigh Poh, Tracy Putoczki, Riley J Morrow, Mariah Alorro, Kyren A Lazarus, Evie F W Yeap, Kelly L Walton, Craig A Harrison, Natalie J Hannan, Amee J George, Colin D Clyne, Matthias Ernst, Andrew M Allen, Ashwini L Chand
Drugs that target the Renin-Angiotensin System (RAS) have recently come into focus for their potential utility as cancer treatments. The use of Angiotensin Receptor Blockers (ARBs) and Angiotensin-Converting Enzyme (ACE) Inhibitors (ACEIs) to manage hypertension in cancer patients is correlated with improved survival outcomes for renal, prostate, breast and small cell lung cancer. Previous studies demonstrate that the Angiotensin Receptor Type I (AT1R) is linked to breast cancer pathogenesis, with unbiased analysis of gene-expression studies identifying significant up-regulation of AGTR1, the gene encoding AT1R in ER+ve/HER2-ve tumors correlating with poor prognosis...
March 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/28416104/multilocular-cystic-renal-cell-carcinoma-pathological-t-staging-makes-no-difference-to-favorable-outcomes-and-should-be-reclassified-bhatt-jr-jewett-ma-richard-po-kawaguchi-s-timilshina-n-evans-a-alibhai-s-finelli-a-j-urol-november-2016-196-5-1350-1355
#9
Oleksandr N Kryvenko
OBJECTIVE: We evaluated survival outcomes of cystic/multilocular cystic renal cell carcinomas in a long-term population-based study based on size and pathological tumor stage. MATERIALS AND METHODS: We, retrospectively, reviewed a provincial cancer registry of all histologically proven cases of multilocular cystic renal cancers treated surgically between 1995 and 2008. All cases of cystic necrosis were excluded from study. Primary end points were overall- and cancer-specific survival estimated using Kaplan-Meier curves...
April 13, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28412331/are-we-using-the-best-tumor-size-cut-points-for-renal-cell-carcinoma-staging
#10
Bimal Bhindi, Christine M Lohse, Ross J Mason, Mary E Westerman, John C Cheville, Matthew K Tollefson, Stephen A Boorjian, R Houston Thompson, Bradley C Leibovich
OBJECTIVE: To compare the predictive ability for oncologic outcomes among current tumor size cut-points and clinically relevant alternatives in order to determine which are optimal. METHODS: Patients who underwent radical or partial nephrectomy between 1970-2010 for T1-2Nx/N0M0 renal cell carcinoma (RCC) were identified. Associations between tumor size and progression-free survival (PFS) and cancer-specific survival (CSS) were evaluated using Kaplan-Meier analyses and Cox models...
April 12, 2017: Urology
https://www.readbyqxmd.com/read/28411071/predictive-nomogram-for-recurrence-following-surgery-for-non-metastatic-renal-cell-cancer-with-tumor-thrombus
#11
E Jason Abel, Timothy A Masterson, Jose A Karam, Viraj A Master, Vitaly Margulis, Ryan Hutchinson, C Adam Lorentz, Evan Bloom, Tyler M Bauman, Christopher G Wood, Michael L Blute
BACKGROUND: Following surgery for non-metastatic renal cell carcinoma (RCC) with tumor thrombus, the risk of recurrence is significant but variable among individual patients. The purpose of this study is to develop and validate a predictive nomogram for individual estimation of recurrence risk following surgery for RCC with venous tumor thrombus. METHODS: Comprehensive data was collected for non-metastatic RCC patients with thrombus treated at 5 institutions from 2000-2013...
April 11, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28410988/fc-optimized-anti-cd25-depletes-tumor-infiltrating-regulatory-t-cells-and-synergizes-with-pd-1-blockade-to-eradicate-established-tumors
#12
Frederick Arce Vargas, Andrew J S Furness, Isabelle Solomon, Kroopa Joshi, Leila Mekkaoui, Marta H Lesko, Enrique Miranda Rota, Rony Dahan, Andrew Georgiou, Anna Sledzinska, Assma Ben Aissa, Dafne Franz, Mariana Werner Sunderland, Yien Ning Sophia Wong, Jake Y Henry, Tim O'Brien, David Nicol, Ben Challacombe, Stephen A Beers, Samra Turajlic, Martin Gore, James Larkin, Charles Swanton, Kerry A Chester, Martin Pule, Jeffrey V Ravetch, Teresa Marafioti, Karl S Peggs, Sergio A Quezada
CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies have displayed limited activity against established tumors. We demonstrated that CD25 expression is largely restricted to tumor-infiltrating Treg cells in mice and humans. While existing anti-CD25 antibodies were observed to deplete Treg cells in the periphery, upregulation of the inhibitory Fc gamma receptor (FcγR) IIb at the tumor site prevented intra-tumoral Treg cell depletion, which may underlie the lack of anti-tumor activity previously observed in pre-clinical models...
April 18, 2017: Immunity
https://www.readbyqxmd.com/read/28408238/novel-roles-for-podocalyxin-in-regulating-stress-myelopoiesis-rap1a-and-neutrophil-migration
#13
Pan Li, Aldona A Karaczyn, Rose McGlauflin, Amanda Favreau, Edward Jachimowicz, Calvin Vary, Kailin Xu, Don M Wojchowski, Pradeep Sathyanarayana
Podocalyxin (Podxl) is a CD34 orthologue and cell surface sialomucin with reported roles in renal podocyte diaphragm slit development, vascular cell integrity, and the progression of blood, breast, and prostate cancers. Roles for Podxl during non-malignant hematopoiesis, however, are largely undefined. Presently we have developed a Vav-Cre Podxl knockout mouse model, and report on novel roles for Podxl in governing stress myelopoiesis. At steady-state, Podxl expression among hematopoietic progenitor cells was low-level but was induced by GCSF (granulocyte colony stimulating factor) in myeloid progenitors, and by TPO (thrombopoietin) in HSCs...
April 10, 2017: Experimental Hematology
https://www.readbyqxmd.com/read/28406456/metronomic-cordycepin-therapy-prolongs-survival-of-oral-cancer-bearing-mice-and-inhibits-epithelial-mesenchymal-transition
#14
Nai-Wen Su, Shu-Hua Wu, Chih-Wen Chi, Chung-Ji Liu, Tung-Hu Tsai, Yu-Jen Chen
Cordycepin (3'-deoxyadenosine) is a natural compound abundantly found in Cordyceps sinesis in natural and fermented sources. In this study, we examined the effects of cordycepin in a human oral squamous cell carcinoma (OSCC) xenograft model. Cordycepin was administered in a regular, low-dose and prolonged schedule metronomic therapy. Two doses of cordycepin (25 mg/kg, 50 mg/kg) were administrated five days a week for eight consecutive weeks. The tumor volumes were reduced and survival time was significantly prolonged from 30...
April 13, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/28405130/mechanism-underlying-linezolid-induced-thrombocytopenia-in-a-chronic-kidney-failure-mouse-model
#15
Nao Nishijo, Yasuhiro Tsuji, Kazuhisa Matsunaga, Masahiko Kutsukake, Fumiyasu Okazaki, Shiro Fukumori, Hidefumi Kasai, Yoichi Hiraki, Ippei Sakamaki, Yoshihiro Yamamoto, Yoshiharu Karube, Hideto To
OBJECTIVE: To investigate the relationship between renal function and linezolid (LZD)-induced thrombocytopenia and elucidate the underlying mechanism using a chronic renal disease (CRD) mouse model. MATERIALS AND METHODS: CRD was induced in 5-week-old male Institute of Cancer Research (ICR) mice by 5/6 nephrectomy. After this procedure, LZD (25 and 100 mg/kg) was administered intraperitoneally once every day for 28 days. Platelet counts, white blood cell (WBC) counts, and hematocrit (HCT) levels were measured every 7 days...
January 2017: Journal of Pharmacology & Pharmacotherapeutics
https://www.readbyqxmd.com/read/28402510/growth-patterns-of-pulmonary-metastases-should-we-adjust-resection-techniques-to-primary-histology-and-size-%C3%A2
#16
Stefan Welter, Elias Arfanis, Daniel Christoph, Thomas Hager, Christian Roesel, Clemens Aigner, Gerhard Weinreich, Dirk Theegarten
OBJECTIVES: Safety margins in pulmonary metastasectomy are not yet well defined. We hypothesize that histological subtype, size of the lesion and local growth characteristics must be taken into consideration during metastasectomy. This study was conducted to examine and classify growth patterns at resection margins and define the relationships between aggressive local growth, metastasis size and local recurrence to direct metastasectomy. METHODS: Histologic sections of pulmonary metastases were prospectively collected and haematoxylin-eosin stains were systematically evaluated and classified by their pattern of lung tissue infiltration...
April 11, 2017: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/28399699/prognostic-and-discriminative-power-of-the-7th-tnm-classification-for-patients-with-surgically-treated-papillary-renal-cell-carcinoma-results-of-a-multi-institutional-validation-study-corona-subtype-project
#17
Matthias May, Cristian Surcel, Umberto Capitanio, Paolo Dell'Oglio, Tobias Klatte, Shahrokh Shariat, Thorsten Ecke, Ingmar Wolff, Daniel Vergho, Nina Wagener, Nina Huck, Sascha Pahernik, Stefan Zastrow, Manfred Wirth, Hendrik Borgmann, Axel Haferkamp, Mireia Musquera, Laura M Krabbe, Edwin Herrmann, Anna Scavuzzo, Cristian Mirvald, Georg Hutterer, Richard Zigeuner, Christian G Stief, Raphaela Waidelich, Luca Cindolo, Krystina Kalusova, Sabine D Brookman-May
OBJECTIVE: Studies on the prognostic reliability of the Union for International Cancer Control tumor, node, metastasis (TNM) staging system for renal cell carcinoma (RCC) predominantly focus on clear-cell RCC. Therefore, the aim of this study was to investigate whether the oncological prognosis of surgically treated papillary RCC (papRCC) patients is reliably given by the current TNM system, by analyzing the largest database reported to date. MATERIALS AND METHODS: Data on 2325 papRCC patients who underwent surgical treatment in 1984- 2015 were collated from 17 international centers (median follow-up 47 months)...
April 12, 2017: Scandinavian Journal of Urology
https://www.readbyqxmd.com/read/28399109/tyrosine-kinase-targeting-drugs-associated-heart-failure
#18
N Gronich, I Lavi, O Barnett-Griness, W Saliba, D R Abernethy, G Rennert
BACKGROUND: The impact of cancer therapies on cardiac disease in the general adult cancer survivor population is largely unknown. Our objective was to evaluate which tyrosine kinase-targeting drugs are associated with greater risk for new-onset heart failure (HF). METHODS: A nested case-control analysis was conducted within a cohort of 27 992 patients of Clalit Health Services, newly treated with a tyrosine kinase-targeting, and/or chemotherapeutic drug, for a malignant disease, between 1 January 2005 and 31 December 2012...
April 11, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28398843/treatment-satisfaction-and-adherence-to-oral-chemotherapy-in-patients-with-cancer
#19
Jamie M Jacobs, Nicole A Pensak, Nora J Sporn, James J MacDonald, Inga T Lennes, Steven A Safren, William F Pirl, Jennifer S Temel, Joseph A Greer
PURPOSE: Although patients with cancer overwhelming prefer oral to intravenous chemotherapy, little is known about adherence to oral agents. We aimed to identify the rates and correlates of adherence in patients with diverse malignancies. MATERIALS AND METHODS: Ninety patients with chronic myeloid leukemia or metastatic renal cell carcinoma, non-small-cell lung cancer, or breast cancer enrolled in this prospective, single-group, observational study of medication-taking behaviors...
April 11, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28398494/impact-of-lymph-node-dissection-on-clinical-outcomes-during-nephroureterectomy-in-patients-with-clinically-node-negative-upper-urinary-tract-urothelial-cancer-subanalysis-of-a-multi-institutional-nationwide-case-series-of-the-japanese-urological-association
#20
Junichi Inokuchi, Masatoshi Eto, Tomohiko Hara, Hiroyuki Fujimoto, Hiroyuki Nishiyama, Jun Miyazaki, Eiji Kikuchi, Shiro Hinotsu, Takuya Koie, Chikara Ohyama
Objective: To evaluate the impact of lymph node dissection (LND) on the clinical outcomes during radical nephroureterectomy (RNU) in patients with clinically node-negative upper urinary tract urothelial cancer (UTUC). Methods: Within the nationwide case series of the Japanese Urological Association, which comprises 1509 patients with UTUC diagnosed in 2005, we identified 823 patients with clinically node-negative UTUC who underwent RNU. The extent of limited LND was defined as the renal hilar region only for renal pelvic cancer and as either the pelvic region or para-aortic/paracaval region only for ureteral cancer, while the extent of wider LND was defined as at least one perilesional LND region in addition to limited LND...
April 7, 2017: Japanese Journal of Clinical Oncology
keyword
keyword
113910
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"